Werewolf Therapeutics
HOWL
62 hedge funds and large institutions have $41.6M invested in Werewolf Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 21 reducing their positions, and 10 closing their positions.
71% more capital invested
Capital invested by funds: $24.3M → $41.6M (+$17.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.57% less ownership
Funds ownership: 49.73% → 46.16% (-3.6%)
5% less funds holding
Funds holding: 65 → 62 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
52% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$212K |
| 2 |
Renaissance Technologies
New York
|
+$191K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$150K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$64K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$520K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$409K |
| 3 |
BlackRock
New York
|
-$357K |
| 4 |
Goldman Sachs
New York
|
-$229K |
| 5 |
Jane Street
New York
|
-$146K |
HOWL Hedge Fund Activity: Q3 2025 in Review
62 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q3 2025, worth a combined $41.6M — up 71% from $24.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HOWL and 8 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 10 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $212K. The largest seller was Millennium Management, cutting an estimated $520K.
- 62 institutional investors held Werewolf Therapeutics (HOWL) as of Q3 2025, down from 65 in Q2 2025.
- Funds reported $41.6M of Werewolf Therapeutics stock for Q3 2025, up 71% quarter-over-quarter.
- 8 funds opened new Werewolf Therapeutics positions in Q3 2025 and 10 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $212K added.
- The largest Werewolf Therapeutics seller in Q3 2025 was Millennium Management, an estimated $520K sold.
Based on aggregated 13F filings for Q3 2025.